CORC

在结果中检索

CORC

浏览/检索结果: 共17条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression 期刊论文
2019, 卷号: 145, 期号: 6, 页码: 1569-1579
作者:  Schuler, Martin;  Tan, Eng-Huat;  O'Byrne, Kenneth;  Zhang, Li;  Boyer, Michael
收藏  |  浏览/下载：20/0  |  提交时间：2020/01/03
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) 期刊论文
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2018, 卷号: 11, 期号: 1
作者:  Wu, Yi-Long;  Hirsh, Vera;  Sequist, Lecia V.;  Hu, Cheng-Ping;  Feng, Jifeng
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/04
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) 期刊论文
The Patient - Patient-Centered Outcomes Research, 2018, 卷号: 11, 期号: 1, 页码: 131-141
作者:  Wu, Yi-Long;  Hirsh, Vera
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/03
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 期刊论文
BRITISH JOURNAL OF CANCER, 2017, 卷号: 116, 期号: 2
作者:  Wu, Yi-Long;  Sequist, Lecia V.;  Hu, Cheng-Ping;  Feng, Jifeng;  Lu, Shun
收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 期刊论文
British Journal of Cancer, 2017, 卷号: 116, 期号: 2, 页码: 175-185
作者:  Wu, Yi-Long*;  Sequist, Lecia V;  Hu, Cheng-Ping;  Feng, Jifeng;  Lu, Shun
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/03
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer 期刊论文
2017, 卷号: 2, 期号: 3, 页码: e000219
作者:  Blackhall Fiona;  Ross Camidge D;  Shaw Alice T;  Soria Jean-Charles;  Solomon Benjamin J
收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03
First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7 期刊论文
2017, 卷号: 12, 期号: 1, 页码: S335-S336
作者:  Park, Keunchil;  Tan, Eng Huat;  Zhang, Li;  Hirsh, Vera;  O'Byrne, Ken
收藏  |  浏览/下载：7/0  |  提交时间：2020/01/03
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial 期刊论文
2016, 卷号: 17, 期号: 5, 页码: 577-589
作者:  Park, Keunchil;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li;  Boyer, Michael
收藏  |  浏览/下载：4/0  |  提交时间：2020/01/04
First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 期刊论文
2016, 卷号: 34, 期号: 15
作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li
收藏  |  浏览/下载：6/0  |  提交时间：2020/01/04
First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 会议论文
JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20
作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li
收藏  |  浏览/下载：7/0  |  提交时间：2020/01/04

©版权所有 ©2017 CSpace - Powered by CSpace